{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:41:55Z","timestamp":1793889715703,"version":"4.8.0"},"reference-count":58,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA125123"],"award-info":[{"award-number":["P30-CA125123"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50-CA186784-07"],"award-info":[{"award-number":["P50-CA186784-07"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL092332"],"award-info":[{"award-number":["T32HL092332"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Adopt-A-Scientist Funding","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"International Medical Research Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,11,18]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Oncolytic adenoviruses (OAds) are the most clinically tested viral vectors for solid tumors. However, most clinically tested \u201cArmed\u201d OAds show limited antitumor effects in patients with various solid tumors even with increased dosages and multiple injections. We developed a binary oncolytic\/helper-dependent adenovirus system (CAdVEC), in which tumors are coinfected with an OAd and a non-replicating helper-dependent Ad (HDAd). We recently demonstrated that a single low-dose CAdVEC expressing interleukin-12, programmed death-ligand 1 blocker, and HSV thymidine kinase safety switch (CAdTrio) induces significant antitumor effects in patients, including complete response. Similar to previous OAd studies, all patients primarily amplified Ad-specific T cells after treatment however, CAdVEC was still able to induce clinical responses even given at a 100-fold lower dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To address the mechanisms of CAdTrio-mediated antitumor effect in patients, we analyzed patients\u2019 samples using Enzyme-linked immunosorbent spot (ELISpot) to measure T-cell specificity and quantitative polymerase chain reaction (qPCR) to measure CAdVEC viral genome copies at tumor sites. We then evaluated potential mechanisms of CAdVEC efficacy in vitro using live-cell imaging. Based on those results, we developed a new CAdVEC additionally expressing a T-cell engager molecule targeting CD44v6 to redirect tumor-infiltrating irrelevant T cells against cancer stem cell populations (CAdTetra) for further improvement of local CAdVEC treatment. We tested its efficacy against different cancer types both in vitro and in vivo including Ad pre-immunized humanized mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found that HDAd-infected cells escape Ad-specific T-cell recognition with enhanced tumor-specific T-cell activity through immunomodulatory transgenes. Since CAdVEC treatment initially amplified Ad-specific T cells in patients, we re-direct these virus-specific T cells to target tumor cells by additionally expressing CD44v6.BiTE from CAdTetra. CAdTetra significantly controlled tumor growth, repolarizing local and systemic responses against cancer cells in both immunologically \u201chot\u201d and \u201ccold\u201d tumor models and also induced immunologic memory against rechallenged tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results indicate that CAdTetra effectively induces adaptive T-cell responses against cancer cells by using tumor-infiltrating irrelevant T cells.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-009741","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T21:40:11Z","timestamp":1733780411000},"page":"e009741","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03740256","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03740256","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03740256","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03740256","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03740256","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03740256","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03740256","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03740256","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Daisuke","family":"Morita","sequence":"first","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, TX, USA"},{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USA"},{"name":"Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan"},{"name":"Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Matsumoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Rosewell Shaw","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, TX, USA"},{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USA"},{"name":"Department of Biology, School of Science and Engineering, Benedict College, Columbia, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greyson","family":"Biegert","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, TX, USA"},{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8500-2608","authenticated-orcid":false,"given":"Caroline","family":"Porter","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, TX, USA"},{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-8524","authenticated-orcid":false,"given":"Mae","family":"Woods","sequence":"additional","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridoula","family":"Vasileiou","sequence":"additional","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USA"},{"name":"Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Lim","sequence":"additional","affiliation":[{"name":"Duncan Cancer Center-Breast, Baylor College of Medicine, Houston, TX, USA"},{"name":"Breast Medical Oncology, The UT MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-4199","authenticated-orcid":false,"given":"Masataka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, TX, USA"},{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"2025100312502437000_12.12.e009741.1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100312502437000_12.12.e009741.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"2025100312502437000_12.12.e009741.3","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.155"},{"key":"2025100312502437000_12.12.e009741.4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.omtm.2019.11.001","article-title":"Immunology of Adenoviral Vectors in Cancer Therapy","volume":"15","author":"Shaw","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025100312502437000_12.12.e009741.5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100312502437000_12.12.e009741.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202028"},{"key":"2025100312502437000_12.12.e009741.7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.omto.2021.11.014","article-title":"Current development in adenoviral vectors for cancer immunotherapy","volume":"23","author":"Biegert","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"2025100312502437000_12.12.e009741.8","doi-asserted-by":"crossref","first-page":"14008","DOI":"10.1038\/mto.2014.8","article-title":"Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy","volume":"1","author":"Farzad","year":"2014","journal-title":"Mol Ther Oncolytics"},{"key":"2025100312502437000_12.12.e009741.9","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer","volume":"25","author":"Rosewell Shaw","year":"2017","journal-title":"Mol Ther"},{"key":"2025100312502437000_12.12.e009741.10","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-021-01914-8","article-title":"Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors","volume":"4","author":"Rosewell Shaw","year":"2021","journal-title":"Commun Biol"},{"key":"2025100312502437000_12.12.e009741.11","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade6790","article-title":"Ultralow-dose binary oncolytic\/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies","volume":"9","author":"Wang","year":"2023","journal-title":"Sci Adv"},{"key":"2025100312502437000_12.12.e009741.12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.21.10608-10616.2002"},{"key":"2025100312502437000_12.12.e009741.13","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/mt.2016.67","article-title":"Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy","volume":"24","author":"Taipale","year":"2016","journal-title":"Mol Ther"},{"key":"2025100312502437000_12.12.e009741.14","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.7.3549-3558.2006"},{"key":"2025100312502437000_12.12.e009741.15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/hum.2013.071","article-title":"Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors","volume":"24","author":"Brunetti-Pierri","year":"2013","journal-title":"Hum Gene Ther"},{"key":"2025100312502437000_12.12.e009741.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01901.x"},{"key":"2025100312502437000_12.12.e009741.17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1343378","article-title":"Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy","volume":"15","author":"Zarezadeh Mehrabadi","year":"2024","journal-title":"Front Immunol"},{"key":"2025100312502437000_12.12.e009741.18","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","article-title":"Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors","volume":"28","author":"Porter","year":"2020","journal-title":"Mol Ther"},{"key":"2025100312502437000_12.12.e009741.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1006732107"},{"key":"2025100312502437000_12.12.e009741.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0809-x","article-title":"Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer","volume":"17","author":"Liu","year":"2018","journal-title":"Mol Cancer"},{"key":"2025100312502437000_12.12.e009741.21","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1004"},{"key":"2025100312502437000_12.12.e009741.22","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2018.00097","article-title":"CD44\/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression","volume":"6","author":"Wang","year":"2018","journal-title":"Front Cell Dev Biol"},{"key":"2025100312502437000_12.12.e009741.23","first-page":"1831","article-title":"CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma","volume":"55","author":"Rall","year":"1995","journal-title":"Cancer Res"},{"key":"2025100312502437000_12.12.e009741.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2014.01.009"},{"key":"2025100312502437000_12.12.e009741.25","first-page":"298","article-title":"CD44v6 may influence ovarian cancer cell invasion and migration by regulating the NF\u2011\u03baB pathway","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol Lett"},{"key":"2025100312502437000_12.12.e009741.26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00099","article-title":"CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice","volume":"11","author":"Porcellini","year":"2020","journal-title":"Front Immunol"},{"key":"2025100312502437000_12.12.e009741.27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112769","article-title":"HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy","volume":"14","author":"Rosewell Shaw","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025100312502437000_12.12.e009741.28","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.277"},{"key":"2025100312502437000_12.12.e009741.29","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.096"},{"key":"2025100312502437000_12.12.e009741.30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1577"},{"key":"2025100312502437000_12.12.e009741.31","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.167"},{"key":"2025100312502437000_12.12.e009741.32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","article-title":"Engineered off-the-shelf therapeutic T cells resist host immune rejection","volume":"39","author":"Mo","year":"2021","journal-title":"Nat Biotechnol"},{"key":"2025100312502437000_12.12.e009741.33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3567"},{"key":"2025100312502437000_12.12.e009741.34","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2025100312502437000_12.12.e009741.35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.omto.2020.11.006","article-title":"Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer","volume":"20","author":"Barton","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"2025100312502437000_12.12.e009741.36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3001"},{"key":"2025100312502437000_12.12.e009741.37","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.18632\/oncotarget.2901","article-title":"Immunological data from cancer patients treated with Ad5\/3-E2F-\u039424-GMCSF suggests utility for tumor immunotherapy","volume":"6","author":"Hemminki","year":"2015","journal-title":"Oncotarget"},{"key":"2025100312502437000_12.12.e009741.38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature New Biol"},{"key":"2025100312502437000_12.12.e009741.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-493361"},{"key":"2025100312502437000_12.12.e009741.40","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3023"},{"key":"2025100312502437000_12.12.e009741.41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00201","article-title":"Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer","volume":"6","author":"Misra","year":"2015","journal-title":"Front Immunol"},{"key":"2025100312502437000_12.12.e009741.42","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00205-12"},{"key":"2025100312502437000_12.12.e009741.43","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4051"},{"key":"2025100312502437000_12.12.e009741.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43982-2"},{"key":"2025100312502437000_12.12.e009741.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.06.009"},{"key":"2025100312502437000_12.12.e009741.46","doi-asserted-by":"crossref","first-page":"8685","DOI":"10.1007\/s13277-014-2111-x","article-title":"Increased MTHFD2 expression is associated with poor prognosis in breast cancer","volume":"35","author":"Liu","year":"2014","journal-title":"Tumour Biol"},{"key":"2025100312502437000_12.12.e009741.47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01878","article-title":"Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options","volume":"9","author":"Kabacaoglu","year":"2018","journal-title":"Front Immunol"},{"key":"2025100312502437000_12.12.e009741.48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2731"},{"key":"2025100312502437000_12.12.e009741.49","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08534-1","article-title":"Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy","volume":"10","author":"Rosato","year":"2019","journal-title":"Nat Commun"},{"key":"2025100312502437000_12.12.e009741.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2016.11.008"},{"key":"2025100312502437000_12.12.e009741.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.018"},{"key":"2025100312502437000_12.12.e009741.52","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2022.100258","article-title":"A Single-Cell Atlas of Tumor-Infiltrating Immune Cells in Pancreatic Ductal Adenocarcinoma","volume":"21","author":"Wang","year":"2022","journal-title":"Mol Cell Proteomics"},{"key":"2025100312502437000_12.12.e009741.53","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2015.18"},{"key":"2025100312502437000_12.12.e009741.54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0910"},{"key":"2025100312502437000_12.12.e009741.55","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0405-4"},{"key":"2025100312502437000_12.12.e009741.56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.701006","article-title":"B7-H3\/CD276: An Emerging Cancer Immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"2025100312502437000_12.12.e009741.57","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol Cancer"},{"key":"2025100312502437000_12.12.e009741.58","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.868695","article-title":"The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:50:38Z","timestamp":1759521038000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,9]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/jitc-2024-009741"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009741","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}